Coagulation factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by yellow fever virus infection of hepatocytes

Sara E. Woodson, Alexander Freiberg, Michael R. Holbrook

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Yellow fever virus (YFV) infection poses a great risk to un-vaccinated individuals living or traveling in the endemic regions of Africa and South America. It is estimated that approximately 30,000 people die each year of this disease. The liver is the main target of YFV, where as many as 80% of the hepatocytes may become involved in the infection. The overwhelming infection of the liver is associated with the observed hemorrhagic disease manifestations such as petechiae, ecchymoses, and hematemesis which are all thought to be linked with the observed coagulation abnormalities that include prolonged clotting times, reduction in clotting factors, fibrin-split products (D-dimers) and elevated prothrombin times. Many factors involved in the coagulation pathway are produced by hepatocytes, such as fibrinogen (FBG) and plasminogen activator inhibitor-1 (PAI-1). Both of these proteins have been indicated in another flavivirus related disease, dengue, as having roles related to the bleeding abnormalities observed and overall outcome of infection. In this study we wanted to determine if FBG and PAI-1 expression levels by human hepatocytes was disrupted or altered by infection with either wild-type Asibi or vaccine strain17-D YFVs. Our findings indicate that YFV infection does affect the transcriptional and translational expression of FBG and PAI-1 in human hepatocytes and that these results are further affected by IL-6 during early stages of infection. These results may lead to further understanding of the molecular mechanism associated with bleeding abnormalities observed during late stage YFV infection.

Original languageEnglish (US)
Pages (from-to)155-159
Number of pages5
JournalVirus Research
Volume175
Issue number2
DOIs
StatePublished - Aug 2013

Fingerprint

Yellow fever virus
Blood Coagulation Factors
Plasminogen Activator Inhibitor 1
Virus Diseases
Fibrinogen
Hepatocytes
Infection
Ecchymosis
Hemorrhage
Hematemesis
Flavivirus
Purpura
Dengue
South America
Liver
Prothrombin Time
Fibrin
Interleukin-6
Vaccines
Proteins

Keywords

  • 17-D vaccine
  • Asibi virus
  • Fibrinogen
  • Hepatocytes
  • Plasminogen activator inhibitor-1
  • Yellow fever virus

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases
  • Cancer Research

Cite this

Coagulation factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by yellow fever virus infection of hepatocytes. / Woodson, Sara E.; Freiberg, Alexander; Holbrook, Michael R.

In: Virus Research, Vol. 175, No. 2, 08.2013, p. 155-159.

Research output: Contribution to journalArticle

@article{9f7efd0605e647cab8b94e426c33214a,
title = "Coagulation factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by yellow fever virus infection of hepatocytes",
abstract = "Yellow fever virus (YFV) infection poses a great risk to un-vaccinated individuals living or traveling in the endemic regions of Africa and South America. It is estimated that approximately 30,000 people die each year of this disease. The liver is the main target of YFV, where as many as 80{\%} of the hepatocytes may become involved in the infection. The overwhelming infection of the liver is associated with the observed hemorrhagic disease manifestations such as petechiae, ecchymoses, and hematemesis which are all thought to be linked with the observed coagulation abnormalities that include prolonged clotting times, reduction in clotting factors, fibrin-split products (D-dimers) and elevated prothrombin times. Many factors involved in the coagulation pathway are produced by hepatocytes, such as fibrinogen (FBG) and plasminogen activator inhibitor-1 (PAI-1). Both of these proteins have been indicated in another flavivirus related disease, dengue, as having roles related to the bleeding abnormalities observed and overall outcome of infection. In this study we wanted to determine if FBG and PAI-1 expression levels by human hepatocytes was disrupted or altered by infection with either wild-type Asibi or vaccine strain17-D YFVs. Our findings indicate that YFV infection does affect the transcriptional and translational expression of FBG and PAI-1 in human hepatocytes and that these results are further affected by IL-6 during early stages of infection. These results may lead to further understanding of the molecular mechanism associated with bleeding abnormalities observed during late stage YFV infection.",
keywords = "17-D vaccine, Asibi virus, Fibrinogen, Hepatocytes, Plasminogen activator inhibitor-1, Yellow fever virus",
author = "Woodson, {Sara E.} and Alexander Freiberg and Holbrook, {Michael R.}",
year = "2013",
month = "8",
doi = "10.1016/j.virusres.2013.04.013",
language = "English (US)",
volume = "175",
pages = "155--159",
journal = "Virus Research",
issn = "0168-1702",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Coagulation factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by yellow fever virus infection of hepatocytes

AU - Woodson, Sara E.

AU - Freiberg, Alexander

AU - Holbrook, Michael R.

PY - 2013/8

Y1 - 2013/8

N2 - Yellow fever virus (YFV) infection poses a great risk to un-vaccinated individuals living or traveling in the endemic regions of Africa and South America. It is estimated that approximately 30,000 people die each year of this disease. The liver is the main target of YFV, where as many as 80% of the hepatocytes may become involved in the infection. The overwhelming infection of the liver is associated with the observed hemorrhagic disease manifestations such as petechiae, ecchymoses, and hematemesis which are all thought to be linked with the observed coagulation abnormalities that include prolonged clotting times, reduction in clotting factors, fibrin-split products (D-dimers) and elevated prothrombin times. Many factors involved in the coagulation pathway are produced by hepatocytes, such as fibrinogen (FBG) and plasminogen activator inhibitor-1 (PAI-1). Both of these proteins have been indicated in another flavivirus related disease, dengue, as having roles related to the bleeding abnormalities observed and overall outcome of infection. In this study we wanted to determine if FBG and PAI-1 expression levels by human hepatocytes was disrupted or altered by infection with either wild-type Asibi or vaccine strain17-D YFVs. Our findings indicate that YFV infection does affect the transcriptional and translational expression of FBG and PAI-1 in human hepatocytes and that these results are further affected by IL-6 during early stages of infection. These results may lead to further understanding of the molecular mechanism associated with bleeding abnormalities observed during late stage YFV infection.

AB - Yellow fever virus (YFV) infection poses a great risk to un-vaccinated individuals living or traveling in the endemic regions of Africa and South America. It is estimated that approximately 30,000 people die each year of this disease. The liver is the main target of YFV, where as many as 80% of the hepatocytes may become involved in the infection. The overwhelming infection of the liver is associated with the observed hemorrhagic disease manifestations such as petechiae, ecchymoses, and hematemesis which are all thought to be linked with the observed coagulation abnormalities that include prolonged clotting times, reduction in clotting factors, fibrin-split products (D-dimers) and elevated prothrombin times. Many factors involved in the coagulation pathway are produced by hepatocytes, such as fibrinogen (FBG) and plasminogen activator inhibitor-1 (PAI-1). Both of these proteins have been indicated in another flavivirus related disease, dengue, as having roles related to the bleeding abnormalities observed and overall outcome of infection. In this study we wanted to determine if FBG and PAI-1 expression levels by human hepatocytes was disrupted or altered by infection with either wild-type Asibi or vaccine strain17-D YFVs. Our findings indicate that YFV infection does affect the transcriptional and translational expression of FBG and PAI-1 in human hepatocytes and that these results are further affected by IL-6 during early stages of infection. These results may lead to further understanding of the molecular mechanism associated with bleeding abnormalities observed during late stage YFV infection.

KW - 17-D vaccine

KW - Asibi virus

KW - Fibrinogen

KW - Hepatocytes

KW - Plasminogen activator inhibitor-1

KW - Yellow fever virus

UR - http://www.scopus.com/inward/record.url?scp=84878824672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878824672&partnerID=8YFLogxK

U2 - 10.1016/j.virusres.2013.04.013

DO - 10.1016/j.virusres.2013.04.013

M3 - Article

VL - 175

SP - 155

EP - 159

JO - Virus Research

JF - Virus Research

SN - 0168-1702

IS - 2

ER -